Medtronic Posts Q3 2025 Results: EPS Beats Expectations, Revenue Falls Slightly Short

2 min read | February 19, 2025 12:14 AM PST | By Team Kalkine Media

Medtronic Posts Q3 2025 Results: EPS Beats Expectations, Revenue Falls Slightly Short — Image source: Shutterstock

Financial Performance: Mixed Results

Medtronic’s total revenue came in at $8.29 billion, missing the consensus estimate of $8.32 billion. However, adjusted EPS of $1.39 surpassed the forecasted $1.36, reflecting strong cost management and operational efficiencies.

Year-over-year, revenue increased by 2.5%, with organic growth at 4.1%, signaling steady demand across core business segments despite macroeconomic challenges.

Segment Breakdown: Growth in Key Divisions

Cardiovascular: Revenue reached $3.04 billion, growing 3.7% as reported and 5% organically. Notable gains were seen in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic, both posting mid-single-digit organic growth. Coronary & Peripheral Vascular had a low-single-digit organic increase.
Neuroscience: Revenue rose 4.4% as reported to $2.46 billion, with organic growth of 5.2%. The Neuromodulation division led with a low-double-digit increase, while Cranial & Spinal Technologies saw mid-single-digit growth, and Specialty Therapies posted a low-single-digit organic increase.
Medical Surgical: The segment saw a decline, with revenue down 1.9% reported to $2.07 billion and 0.4% organically. Surgical & Endoscopy remained flat, while Acute Care & Monitoring saw a low-single-digit organic decline.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.